CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED

Charles River Discovery Research Services UK Limited provides specialized research and development services focused on preclinical biomedical innovation, particularly in the area of targeted cancer therapeutics. Their core capabilities center on antibody-based drug discovery, including the design, evaluation, and preclinical validation of monoclonal antibodies for oncology applications. The contractor leverages advanced molecular biology techniques and in vitro/in vivo modeling to support the development of precision oncology candidates, with demonstrated experience in the technical evaluation of novel antibody constructs such as the A10 antibody targeting epidermal growth factor receptor-positive cancer cells. Their work integrates pharmacokinetic and pharmacodynamic analysis, biomarker identification, and translational research workflows aligned with FDA and EMA regulatory pathways, positioning them as a niche provider in early-stage biopharmaceutical development. The contractor has performed work for the Program Support Center Acquisition Management Service, supporting federal biomedical research initiatives through direct procurement and technical collaboration. This engagement reflects a relationship rooted in specialized scientific services rather than broad institutional contracting, suggesting a targeted, project-based partnership model with agencies engaged in cancer research and therapeutic development. Their primary NAICS classification, 541715, indicates a focus on scientific research and development in the life sciences, specifically in biomedical and pharmaceutical R&D. They operate within the preclinical oncology research segment, serving government-funded programs seeking external expertise in antibody therapeutics and targeted cancer interventions. Charles River Discovery Research Services UK Limited is structured as a non-certified, UK-based entity with no active government certifications on record. Their geographic presence is centered in Saffron Walden, UK, and they serve the U.S. federal market through direct contract awards, functioning as a specialized international provider of preclinical discovery services to U.S. biomedical research agencies.